Our Expert Videos

Presentation R&D Day

Dr. James Welsh

WHAT LIES AHEAD FOR IMMUNO-ONCOLOGY

Many tumors are not adequately responsive to checkpoint inhibitors and other IO approaches. Can we use radiation and nanoparticles to stimulate an immune response against a tumor? Watch video #5 to hear Dr. James Welsh to learn what advances are being developed in immunooncology, radiotherapy and nanomedicine.

Dr. Tanguy Seiwert

STUDY 1100: CAN WE TURN COLD TUMORS HOT?

Once in a while, we as researchers must try something new and has the potential to revolutionize the treatment landscape. Once in a while, we as researchers must try something new and has the potential to revolutionize the treatment landscape. The 1100 trial selects patients who have failed radiation and are not likely to be cured.Preclinical and clinical data suggest that NBTXR3 has the potential to turn CPI non-responders into responders, and that these nanoparticles help induce immunogenesis, turning “cold” tumors into “hot” ones, allowing the immune system to recognize the tumor and get equipped against it. Dr. Tanguy Seiwert maps out Nanobiotix’s Phase I/II 1100 trial studying the potential immunogenic effect of NBTXR3 in head & neck cancer and non-small cell lung cancer patients.

Laurent Levy, PHD

BIRTH OF NBTXR3

“20 years ago, I asked myself: Can we influence a cell by impacting its physics at the subcellular level?” Laurent Levy examines the importance of asking different questions, and how this leads to disruptive healthcare. This video presents how NBTXR3’s technology came into being, and the developments of NBTXR3 in clinical trials.

Virtual KOL Discussion of Updated Study 1100 Data at ASCO 2021


Jeffrey Bockman, PhD, Laurent Levy, Jared Weiss, MD, Tanguy Seiwert, MD, James Welsh, MD, Colette Shen, MD

Virtual KOL Discussion of New Immunotherapy data at ASCO 2021

Nanobiotix hosted a virtual investor event featuring several key opinion leaders, including study investigators. This discussion expand on the new immunotherapy results providing additional detail and clinical perspective, following the ASCO 2021 presentation

Laurent Levy, Dr. Colette Shen, Dr. Jared Weiss, Dr. James Welsh

STUDY 1100 PHASE I RESULTS WEBINAR

A webinar was held on Friday, 13 November 2020 presenting a deep-dive on the positive first results of NBTXR3 in Immuno-Oncology. Moderated by Dr. Jeff Bockman, EVP, Oncology Practice Head, Cello Health, speakers include Laurent Levy, CEO, Nanobiotix, Dr. Colette Shen, Assistant Professor, Radiation Oncology and Dr. Jared Weiss, Assistant Professor of Medicine, both from UNC Lineberger Comprehensive Cancer Center and Dr. James Welsh, Radiation Oncologist & Professor, The University of Texas, MD Anderson Cancer Center.

Cancer Network Interview


Laurent Levy and Tanguy Lim-Seiwert, MD,

CANCER NETWORK INTERVIEW

Cancer Network spoke with Laurent Levy, CEO of Nanobiotix, and Tanguy Lim-Seiwert, MD, of John Hopkins Medicine, to discuss the potential of NBTXR3 designed to destroy tumors through physical cell death when activated by radiotherapy.

Cancer Network Interview


Laurent Levy and Tanguy Lim-Seiwert, MD,

CANCER NETWORK INTERVIEW

Cancer Network spoke with Laurent Levy, CEO of Nanobiotix, and Tanguy Lim-Seiwert, MD, of John Hopkins Medicine, to discuss the potential of NBTXR3 designed to destroy tumors through physical cell death when activated by radiotherapy.

SFRO E-Symposium


The French society of Radiation Oncology (SFRO) was created in 1990 and serves the purpose of promoting the teaching of radiation oncology in France.

Laurent Levy and Juliette Thariat, M.D, Ph.D.

SFRO E-SYMPOSIUM

Nanobiotix presented during the French Society of Radiation Oncology annual congress on Developping the potential of radiation therapy with NBTXR3 in head and neck cancers.

Laurent Levy, PHD

TEDx Paris

17 years ago, Laurent LEVY, Pioneer of Nanomedicine, researcher and entrepreneur, was one of the first entrepreneurs to believe and work on the development of nanomedicines for cancer treatment. Laurent Levy holds a Doctorate in Physical Chemistry, specializing in nanomaterials, from the Pierre and Marie Curie University (Université Paris VI Pierre et Marie Curie) in Paris and from the CEA (Commissariat à l’Énergie Atomique et aux Énergies Alternatives). In 2003, he founded NANOBIOTIX, one of the most promising biotechs in France.

TEDx Paris


This TEDx talk with Laurent Levy was filmed on 28 November 2013 at “Gaîté Lyrique” in Paris. Discover the video of Laurent Levy, CEO of Nanobiotix on the importance of nanomedicine for the treatment of cancers.

Laurent Levy, PHD

TEDx Paris

17 years ago, Laurent LEVY, Pioneer of Nanomedicine, researcher and entrepreneur, was one of the first entrepreneurs to believe and work on the development of nanomedicines for cancer treatment. Laurent Levy holds a Doctorate in Physical Chemistry, specializing in nanomaterials, from the Pierre and Marie Curie University (Université Paris VI Pierre et Marie Curie) in Paris and from the CEA (Commissariat à l’Énergie Atomique et aux Énergies Alternatives). In 2003, he founded NANOBIOTIX, one of the most promising biotechs in France.

Français